DNAGinkgo+PlatformTWSTTwist+SynthesisABSIAbsci+AIDesignCRSPCRISPR Therapeutics+EditBEAMBeam+BaseEditNTLAIntellia+InVivoCRBUCaribou+CellTherapyRXRXRecursion+AIILMNIllumina+SeqEDITEditas+GeneFUND.YTD2025$17.3B.Raised
Terminal/Companies/Intellia Therapeutics
publicFounded 2014

Intellia Therapeutics

HQ: Cambridge, MA, USACEO: John LeonardHeadcount: 600+intelliatx.com
Funding Summary
Total Funding
$1B+
Latest Valuation
~$3B (public market cap)
About

Leading in vivo CRISPR gene editing company with the first clinical data showing CRISPR can edit genes directly inside the human body (NTLA-2001 for ATTR). Co-founded by Jennifer Doudna.

Products
in-vivo-crispr-editing
Recent Developments
Recent developments are auto-populated from tagged articles in the Newsfeed. Browse all news →